glucagon has been researched along with exenatide in 175 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (exenatide) | Trials (exenatide) | Recent Studies (post-2010) (exenatide) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 2,806 | 383 | 2,016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (14.29) | 18.2507 |
| 2000's | 93 (53.14) | 29.6817 |
| 2010's | 50 (28.57) | 24.3611 |
| 2020's | 7 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eng, J; Raufman, JP; Singh, G; Singh, L | 1 |
| Eng, J; Raufman, JP; Singh, G | 1 |
| Fehmann, HC; Göke, B; Göke, R; Kolligs, F | 1 |
| Classen, M; Dehne, K; Eng, J; Holst, JJ; Raufman, JP; Riedel, T; Schepp, W; Schmidtler, J; Schusdziarra, V | 1 |
| Arnold, R; Bothe-Sandfort, E; Eissele, R; Eng, J; Göke, B; Koop, H | 1 |
| Boyd, AE; Fehmann, HC; Göke, B; Jiang, J; Schweinfurth, J; Wheeler, MB | 1 |
| Allescher, HD; Classen, M; Dehne, K; Holst, JJ; Polack, A; Schepp, W; Schmidtler, J; Schusdziarra, V | 1 |
| Eng, J; Fehmann, HC; Göke, B; Göke, R; Krause, M; Linn, T; Schmidt, H | 1 |
| Göke, R; Larsen, PJ; Mikkelsen, JD; Sheikh, SP | 2 |
| Graziano, MP; Hey, PJ; Strader, CD | 1 |
| Barragán, JM; Blázquez, E; Eng, J; Rodríguez, RE | 1 |
| Chen, YE; Drucker, DJ | 1 |
| Alcántara, AI; Clemente, F; Delgado, E; López-Delgado, MI; Luque, MA; Malaisse, WJ; Morales, M; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Beday, A; Eng, J; Montrose-Rafizadeh, C; Pritchette, LA; Rodgers, BD; Yang, H | 1 |
| Adams, LG; Montrose, MH; Montrose-Rafizadeh, C; Roth, J; Wang, Y; Yang, H | 1 |
| Bredenbröker, D; Fehmann, HC; Storm, B; Tackenberg, B; von Wichert, P; Wagner, U | 1 |
| Beak, SA; Bloom, SR; Buckingham, JC; Ghatei, MA; Heath, MM; Morgan, DG; Small, CJ; Smith, DM; Taylor, AD | 1 |
| Pohl, M; Wank, SA | 1 |
| Habener, JF; Holz, GG | 1 |
| De Ore, KA; Egan, JM; Garant, MJ; Greig, NH; Holloway, HW; Jani, D; Wang, Y; Zhou, J | 1 |
| Bhavsar, S; Bodkin, N; Denaro, M; Gedulin, BR; Hansen, B; Jodka, C; Young, AA | 1 |
| Chow, BK; Chow, LS; Du, X; Mojsov, S; Ngan, ES; Tse, DL; Wei, Y | 1 |
| Bonner-Weir, S; Habener, JF; Stoffers, DA; Xu, G | 1 |
| Egan, JM; Pineyro, MA; Wang, X; Zhou, J | 1 |
| Ito, T; Kawai, K; Kawakami, S; Nakabayashi, H; Nakagawa, A; Niijima, A; Nishizawa, M; Uchida, K | 1 |
| Alvarez, E; Blázquez, E; Chowen, JA; Eng, J; Gómez, R; Maestre, O; Muñoz, RM; Navarro, M; Rodriquez de Fonseca, F; Roncero, I | 1 |
| Ebinger, M; Fehmann, HC; Fussgaenger, RD; Jehle, DR; Jehle, PM | 1 |
| Bonner-Weir, S; Drucker, DJ; Egan, JM; Habener, JF; Hussain, MA; Kieffer, TJ; Stoffers, DA | 1 |
| Jodka, C; Parkes, DG; Pittner, R; Smith, P; Young, A | 1 |
| Bloom, SR; Brynes, AE; Davis, R; Edwards, CM; Frost, GS; Ghatei, MA; Seal, LJ; Stanley, SA | 1 |
| Bailbé, D; Kergoat, M; Meile, MJ; Portha, B; Tourrel, C | 1 |
| Drucker, DJ | 1 |
| Anderson, GH; Brubaker, PL; Choi, YH; Peters, CT | 1 |
| Andersen, NH; Fesinmeyer, RM; Neidigh, JW; Prickett, KS | 1 |
| Andersen, NH; Brodsky, Y; Neidigh, JW; Prickett, KS | 1 |
| Chepurny, OG; Holz, GG | 2 |
| Bloom, SR; Coppock, HA; Ghatei, MA; Khoshdel, Z; Owji, AA; Panjehshahin, MR; Sanea, F; Shojaee Fard, M; Smith, DM | 1 |
| Chen, D; Egan, JM; Greig, NH; Lahiri, DK; Perry, T; Shaw, KT; Zhou, J | 1 |
| Donnelly, R; Gray, S; Idris, I; Patiag, D | 1 |
| Bailbe, D; Kergoat, M; Lacorne, M; Meile, MJ; Portha, B; Tourrel, C | 1 |
| Göke, B; Göke, R; Hupe-Sodmann, K; McGregor, GP; Thum, A; Voigt, K | 1 |
| Acitores, A; González, N; Luque, MA; Márquez, L; Morales, M; Redondo, A; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Doyle, ME; Egan, JM; Pineyro, MA; Wang, X; Zhou, J | 1 |
| Malendowicz, LK; Nowak, KW | 1 |
| Egan, JM; Greig, NH; Haughey, NJ; Mattson, MP; Perry, T | 1 |
| Adatia, FA; Baggio, LL; Brubaker, PL; Drucker, DJ; Xiao, Q | 1 |
| Carr, RD; Deacon, CF; Gotfredsen, CF; Knudsen, LB; Larsen, MO; Rolin, B; Wilken, M | 1 |
| Taminato, T | 1 |
| Brubaker, PL; Wang, Q | 1 |
| Adkins, AS; Basu, R; Reed, AS; Rizza, RA; Shah, P; Vella, A | 1 |
| Drucker, DJ; Halban, PA; Hansotia, T; Li, Y; Ris, F; Yusta, B | 1 |
| Egan, JM; Elahi, D; Meneilly, GS | 1 |
| Baron, AD; Kim, D; Weyer, C | 1 |
| Donnelly, D; Kuntzsch, A; López de Maturana, R; Rudolph, R; Willshaw, A | 1 |
| Bloomgarden, ZT | 2 |
| Gallwitz, B; Meier, JJ; Nauck, MA | 1 |
| Choi, BJ; Drucker, DJ; Elmquist, JK; Fang, H; Hollenberg, AN; Kishi, T; Lee, CE; Yamamoto, H | 1 |
| Macchi, C; Malendowicz, LK; Nowak, KW; Nussdorfer, GG; Ziolkowska, A; Zyterska, A | 1 |
| Chen, D; Egan, JM; Greig, NH; Lahiri, DK; Mattson, MP; Perry, T; Sambamurti, K | 1 |
| Egido, EM; Marco, J; Rodríguez-Gallardo, J; Silvestre, RA | 1 |
| Aisporna, M; Baron, AD; Bicsak, TA; Buse, JB; Fineman, MS; Gaines, E; Heintz, S; Kim, D; Kolterman, OG; Taylor, K; Wang, Y | 1 |
| Greig, NH; Perry, T | 1 |
| Al-Sabah, S; Donnelly, D | 2 |
| El-kholy, W; MacDonald, PE; Targonsky, ED; Tsushima, RG; Wang, X; Wheeler, MB; Xia, F | 1 |
| Nielsen, LL; Parkes, DG; Young, AA | 1 |
| Abidi, F; Donnelly, D; Findlay, JB; López de Maturana, R; Treece-Birch, J | 1 |
| Baron, A; Kelemen, D; Ruggles, JA | 1 |
| Rachman, J | 1 |
| Kordella, T | 1 |
| Holst, JJ | 1 |
| Edwards, CM | 1 |
| Behme, MT; Dupré, J; McDonald, TJ | 1 |
| Baggio, LL; Brown, TJ; Drucker, DJ; Huang, Q | 1 |
| Brock, B; Degn, KB; Djurhuus, CB; Fineman, M; Grubert, J; Han, J; Juhl, CB; Kim, D; Schmitz, O; Taylor, K | 1 |
| Philips, JC; Radermecker, RP; Scheen, AJ | 1 |
| Pronsati, MP | 1 |
| Chang, CC; Ferber, S; Linning, KD; Madhukar, BV; Olson, LK; Reed, DN; Tai, MH; Trosko, JE | 1 |
| Acuna-Goycolea, C; van den Pol, A | 1 |
| Benjes, CL; Crowley, AR; Gittes, GK; Hembree, MJ; Li, Z; McFall, CR; Mehta, SS; Prasadan, KL; Preuett, BL; Sharp, SL; Tulachan, SS; Yew, KH | 1 |
| Joy, SV; Rodgers, PT; Scates, AC | 1 |
| Baron, AD; Gedulin, BR; Gedulin, G; Nielsen, LL; Nikoulina, SE; Parkes, DG; Smith, PA; Young, AA | 1 |
| Acitores, A; González, N; Sancho, V; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Brubaker, PL; Cao, X; Drucker, DJ; Edlund, H; Li, LX; Li, Y | 1 |
| Baron, AD; Fineman, MS; Kim, DD; Kolterman, OG; Nielsen, LL; Ruggles, JA; Shen, L | 1 |
| Afşar, S; Akkan, AG; Kutluata, N; Ozdaş, SB; Ozyazgan, S | 1 |
| Verspohl, EJ | 1 |
| Bonner-Weir, S; Weir, GC | 1 |
| Benjes, C; Crowley, A; Gittes, G; Hembree, M; McFall, C; Mehta, S; Prasadan, K; Preuett, B; Sharp, S; Tei, E; Tulachan, S; Yew, KH | 1 |
| Keating, GM | 1 |
| Bai, L; Meredith, G; Tuch, BE | 1 |
| González, N; Malaisse, WJ; Sancho, V; Trigo, MV; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Aisporna, M; Baron, AD; Fineman, MS; Kim, D; Nielsen, LL; Taylor, K | 1 |
| Bajaj, M; Briones, M | 1 |
| Beruto, V; Di Girolamo, G; González, C; Keller, G; Santoro, S | 1 |
| Conlon, JM; Flatt, PR; Patterson, S | 1 |
| Drucker, DJ; Sowden, GL; Swoap, SJ; Weinshenker, D | 1 |
| Brendel, MD; Bretzel, RG; Jahr, H; Mergler, S; Plöckinger, U; Singh, V; Strowski, MZ; Wiedenmann, B; Zacharias, S | 1 |
| Mikhail, N | 1 |
| Doyle, ME; Egan, JM | 1 |
| Scheen, AJ | 1 |
| Egido, EM; Hernández, R; Marco, J; Silvestre, RA | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Musi, N; Sriwijitkamol, A; Triplitt, C; Wajcberg, E; Zuo, P | 1 |
| Bergman, RN; Ionut, V; Stefanovski, D; Zheng, D | 1 |
| Guerci, B; Martin, CS | 1 |
| Alejandro, R; Baidal, DA; Cure, PE; Faradji, RN; Froud, T; Mendez, A; Messinger, S; Monroy, K; Pileggi, A; Ponte, GM; Ricordi, C; Selvaggi, G | 1 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| de la Peña, A; Fineman, M; Irie, S; Isaka, Y; Kothare, PA; Linnebjerg, H; Mace, K; Sakata, Y; Shigeta, H; Teng, CH; Uenaka, K; Yamamura, A; Yeo, KP | 1 |
| Bianchi, C; Gentilella, R; Rossi, A; Rotella, CM | 1 |
| Capparelli, E; Fineman, M; Gottschalk, M; Guan, X; Kothare, P; Malloy, J | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Khoo, EY; Macdonald, IA; Mansell, P; Tsintzas, K; Wallis, J | 1 |
| Alejandro, R; Faradji, RN; Froud, T; Mendez, AJ; Messinger, S; Mineo, D; Monroy, K; Pileggi, A; Ricordi, C; Tharavanij, T | 1 |
| Diamant, M; van Genugten, RE; van Raalte, DH | 1 |
| Svec, F | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
| Knudsen, LB | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N; Petz, R; Sriwijilkamol, A; Triplitt, C; Wajcberg, E; Zuo, P | 1 |
| Guo, F; Wang, L; Wei, S; Zhao, R | 1 |
| Gong, M; Li, Y; Tang, L; Xu, W; Zheng, X | 1 |
| Acitores, A; González, N; Gutiérrez-Rojas, I; Moreno, P; Nuche-Berenguer, B; Sancho, V; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Booker Porter, TK; Cirincione, BB; Darsow, T; Diamant, M; Fineman, MS; Kinninger, LA; Mace, KF; Trautmann, ME | 1 |
| Bahekar, R; Dhanesha, N; Dhote, V; Jain, M; Joharapurkar, A; Kshirsagar, S; Shah, G | 1 |
| Bandsma, RH; Dash, S; Lewis, GF; Szeto, L; Xiao, C | 1 |
| Asahara, S; Bartolome, A; Etoh, H; Fuchita, M; Hashimoto, N; Hosooka, T; Inoue, H; Kanno, A; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Mieda, Y; Seino, S; Shimizu, S; Takahashi, H; Teruyama, K | 1 |
| Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V | 1 |
| Fukunari, A; Iwasaki, S; Kakimoto, T; Kimata, H; Utsumi, H | 1 |
| Asada, Y; Kuwayama, H; Ochiiwa, K; Saito, T; ThanThan, S; Yannaing, S; Zhao, H | 1 |
| Kaya-Dagistanli, F; Ozturk, M | 1 |
| Garofolo, F; Mess, JN; Morin, LP | 1 |
| Balas, B; Balena, R; Boldrin, M; Bolli, GB; Charbonnel, B; Gastaldelli, A; Ratner, R; Rosenstock, J | 1 |
| Ghazi, T; Herold, KC; Rink, L; Sherr, JL | 1 |
| Cho, SH; Gu, N; Jang, IJ; Kim, J; Lee, H; Lim, KS; Seol, E; Shin, D; Shin, SG; Yu, KS | 1 |
| Bardram, L; Calatayud, D; Heller, RS; Hvelplund, A; Kaastrup, P; Kirk, RK; Knudsen, LB; Pyke, C; Reedtz-Runge, S; Ørskov, C | 1 |
| Abroun, S; Allahverdi, A; Jafarian, A; Pourpak, Z; Soleimani, M; Taghikhani, M | 1 |
| Fan, H; Gong, N; Ma, AN; Wang, YC; Wang, YX; Xiao, Q; Zhang, CY; Zhu, B | 1 |
| Cantwell, M; Heptulla, RA; Ramchandani, N; Renukuntla, VS; Trast, J | 1 |
| Adeghate, E; Lotfy, M; Rashed, H; Singh, J; Tariq, S; Zilahi, E | 1 |
| Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK | 1 |
| Baretić, M; Troskot, R | 1 |
| Adin, CA; Borin-Crivellenti, S; Gilor, C; Hall, MJ; Rajala-Schultz, P; Rudinsky, AJ | 1 |
| Abadpour, S; Foss, A; Gorman, T; Hoeyem, M; Johansson, L; Korsgren, O; Sahraoui, A; Scholz, H; Skrtic, S; Smith, DM; Winzell, MS | 1 |
| Flatt, PR; Irwin, N; Pathak, V | 1 |
| Benoist, C; Clardy, SM; Iwamoto, Y; Keliher, EJ; Mathis, D; Mohan, JF; Vinegoni, C; Weissleder, R | 1 |
| Akalestou, E; Bloom, SR; Christakis, I; Minnion, JS; Rutter, GA; Solomou, AM | 1 |
| Bjornvad, CR; Cronin, AM; Hoelmkjaer, KM; Holst, JJ; Mandrup-Poulsen, T; Nielsen, DH; Wewer Albrechtsen, NJ | 1 |
| Asare-Bediako, I; Bergman, RN; Broussard, JL; Castro, AV; Ionut, V; Iyer, MS; Kabir, M; Kolka, CM; Liu, H; Mkrtchyan, HJ; Stefanovski, D; Woolcott, OO; Wu, Q | 1 |
| Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
| Astiarraga, B; Camastra, S; Ciociaro, D; Ferrannini, E; Frascerra, S; Gastaldelli, A; Mari, A; Tura, A | 1 |
| Bossart, M; Dudda, A; Elvert, R; Evers, A; Glien, M; Haack, T; Henkel, B; Kadereit, D; Kurz, M; Lorenz, K; Lorenz, M; Stengelin, S; Wagner, M | 1 |
| Ding, B; Jiang, LL; Jing, T; Lee, KO; Ma, JH; Wang, SQ; Wu, JD; Ye, L; Zhu, J | 1 |
| Bahekar, R; Jain, M; Joharapurkar, A; Kadam, S; Kshirsagar, S; Pandey, D; Patel, D; Patel, H; Patel, M; Patel, V; Ranvir, R; Sutariya, B | 1 |
| Cheng, W; Li, D; Liu, Z; Ma, L; Shang, Y; Shen, C; Wang, X; Yin, K; Zhao, D | 1 |
| Jun, HS; Lee, YS | 1 |
| Li, D; Li, L; Ma, L; Shang, Y; Shen, C; Yu, Y; Zhao, D | 1 |
| Christiansen, CB; Drucker, DJ; Gabe, MBN; Holst, JJ; Larsen, O; Rosenkilde, MM; Svendsen, B | 1 |
| Abrahamsson, N; Almby, KE; Eriksson, JW; Hammar, U; Karlsson, FA; Lundqvist, MH; Panagiotou, A; Sundbom, M; Thombare, K; Wiklund, U | 1 |
| Brooks, A; Guyton, J; Jeon, M | 1 |
| Craig, SL; Flatt, PR; Gault, VA; Hasib, A; Irwin, N; Khan, D | 1 |
| Anderson, JN; Bao, Y; Bartlett, JR; Bissonnette, S; Briant, AR; Carcel, C; Chan, K; Chen, H; Chen, L; Cheng, C; Chrétien, M; Conway Fitzgerald, A; Cyr, Y; Du, Y; El-Sayed, YY; Endo, T; Faraj, M; Fujimoto, K; Girsen, A; Goto, H; Hashimoto, D; Hayasaka, K; Hayase, E; Herrmann, N; Hidaka, D; Holst, JJ; Igbinosa, I; Iijima, H; Jeandidier, N; Jeong, DY; Jeong, GT; Joubert, M; Kagawa, I; Kahata, K; Kaushik, LK; Kim, SK; Kim, SR; Kuang, Y; Laird, M; Lamantia, V; Li, P; Li, Y; Li, Z; Lindsay, SE; Liu, X; Loizon, E; Lu, Z; Lyell, DJ; Ma, J; Magnani, CJ; Mahalingam, AK; Mandal, N; Mayer, G; Michimata, R; Ngo Sock, ET; Okada, K; Onozawa, M; Opigez, V; Palanisamy, M; Parienti, JJ; Park, YR; Pavlikova, B; Peyro Saint Paul, L; Ramsahye, N; Reyes, GA; Reznik, Y; Richardson, MT; Samo, IA; Sarkar, R; Shendge, AK; Shimizu, C; Shiratori, S; Steinberg, JR; Sugita, J; Sukwong, P; Sun, X; Sunagoya, K; Sunwoo, IY; Svendsen, B; Tang, L; Tang, Z; Teshima, T; Totée, C; Turner, BE; Unno, M; Vidal, H; Wang, C; Wang, M; Wang, S; Wang, X; Wang, Z; Wassef, H; Weeks, BT; Wong Chi Man, M; Xu, C; Xu, W; Yamamoto, S; Yu, H; Zhang, WY; Zhang, X; Zhong, Y | 1 |
| Gao, L; Jin, H; Li, J; Li, Y; Wang, S; Xie, M; Yang, H; Ye, Y | 1 |
| Ai, M; Aviello, G; Boudjadja, MB; Coskun, T; Costa, A; Culotta, I; D'Agostino, G; Emmerson, PJ; Hodson, DJ; Hunter, J; Luckman, SM; Nunn, N; Snider, BM; Valencia-Torres, L | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Flatt, PR; Franklin, ZJ; Irwin, N; Lafferty, RA; McShane, LM; O'Harte, FPM | 1 |
| Ambery, P; Jermutus, L; Lindsay, RT; Murray, AJ | 1 |
| Aydin, BK; Bergsten, P; Cerenius, SY; Chowdhury, A; Ciba, I; Forslund, A; Gjessing, ES; Gomahr, J; Heu, V; Kristinsson, H; Manell, H; Mörwald, K; Stenlid, R; Weghuber, D; Wen, Q | 1 |
26 review(s) available for glucagon and exenatide
| Article | Year |
|---|---|
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Delivery Systems; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Technology, Pharmaceutical; Venoms | 2001 |
[Glucagon-like peptide-1 (GLP-1) receptor].
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Polymorphism, Genetic; Protein Precursors; Receptors, Glucagon; Venoms | 2002 |
Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Topics: Amyloid; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Design; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Peptide Fragments; Peptides; Postprandial Period; Protein Precursors; Venoms | 2002 |
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Peptide Fragments; Peptides; Protease Inhibitors; Protein Precursors; Venoms | 2003 |
The glucagon-like peptides: a double-edged therapeutic sword?
Topics: Amino Acid Sequence; Animals; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2003 |
Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2003 |
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Topics: Amino Acid Sequence; Animals; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Molecular Sequence Data; Nutritional Physiological Phenomena; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2004 |
Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration.
Topics: Blood Glucose; Cell Differentiation; Cell Division; Diabetes Mellitus, Type 1; Exenatide; Genetic Therapy; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Immunotherapy; Islets of Langerhans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Stem Cells; Venoms | 2004 |
Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Afferent Pathways; Animals; Appetite; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Hypothalamus; Insulin; Insulin Secretion; Intestinal Mucosa; Islets of Langerhans; Liraglutide; Lizards; Maleimides; Mice; Mice, Knockout; Mice, Obese; Peptide Fragments; Peptides; Proglucagon; Protein Precursors; Rats; Rats, Zucker; Receptors, Glucagon; Venoms | 2004 |
Gut-derived incretin hormones and new therapeutic approaches.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Follow-Up Studies; Forecasting; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Peptide Fragments; Peptides; Protein Precursors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Venoms | 2004 |
Incretin mimetics as emerging treatments for type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2005 |
[Treatment of diabetes mellitus. New developments and hopes].
Topics: Adiponectin; Animals; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glycogen Phosphorylase; Humans; Hypoglycemic Agents; Imidazoles; Insulin; Intercellular Signaling Peptides and Proteins; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2005 |
New sources of pancreatic beta-cells.
Topics: Cell Differentiation; Diabetes Mellitus; Embryo, Mammalian; Embryo, Nonmammalian; Epidermal Growth Factor; Exenatide; Gastrins; Glucagon; Glucagon-Like Peptide 1; Islets of Langerhans; Pancreas; Peptide Fragments; Peptides; Protein Precursors; Regeneration; Stem Cells; Venoms | 2005 |
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Peptides; Randomized Controlled Trials as Topic; Receptors, Glucagon; Venoms | 2006 |
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
Topics: Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Type 2; Drugs, Investigational; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Venoms | 2006 |
Major contributions of comparative endocrinology to the development and exploitation of the incretin concept.
Topics: Amino Acid Sequence; Animals; Anura; Exenatide; Fishes; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Humans; Hypoglycemic Agents; Intestinal Mucosa; Molecular Sequence Data; Peptide Fragments; Peptides; Sequence Alignment; Venoms | 2006 |
Exenatide: a novel approach for treatment of type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin | 2006 |
Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Topics: Animals; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pancreas; Peptides; Receptors, Glucagon; Second Messenger Systems; Venoms | 2007 |
Exenatide: its position in the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptides; Venoms | 2008 |
Exenatide: a review from pharmacology to clinical practice.
Topics: Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Peptides; Randomized Controlled Trials as Topic; Venoms; Weight Loss | 2009 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Liraglutide: the therapeutic promise from animal models.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice; Mice, Obese; Peptides; Rats; Rats, Zucker; Receptors, Glucagon; Swine; Swine, Miniature; Venoms | 2010 |
How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Topics: Anti-Obesity Agents; Bariatric Surgery; Biological Transport; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Kidney Tubules, Proximal; Microvilli; Multicenter Studies as Topic; Obesity; Peptides; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Weight Loss | 2015 |
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Treatment Outcome; Weight Loss | 2019 |
20 trial(s) available for glucagon and exenatide
| Article | Year |
|---|---|
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
Topics: Aged; Blood Glucose; Body Composition; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Peptides; Venoms | 2003 |
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Fasting; Female; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Triglycerides; Venoms | 2003 |
Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
Topics: Adult; Aged; Analysis of Variance; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Drug Administration Schedule; Exenatide; Female; Gastric Emptying; Glucagon; Humans; Injections, Subcutaneous; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Time Factors; Venoms | 2004 |
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Topics: Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Exenatide; Fatty Acids, Nonesterified; Glucagon; Humans; Hydrocortisone; Hypoglycemia; Infusions, Intravenous; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Peptides; Venoms | 2004 |
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Gastric Emptying; Glucagon; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Nausea; Peptides; Postprandial Period; Single-Blind Method; Venoms; Vomiting | 2005 |
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Topics: Adult; Aged; Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Infusions, Parenteral; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Peptides; Proinsulin; Venoms | 2005 |
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Topics: Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Exenatide; Female; Glucagon; Half-Life; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Japan; Male; Middle Aged; Nausea; Peptides; Single-Blind Method; Time Factors; Treatment Outcome; Venoms; Vomiting | 2008 |
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Topics: Adolescent; Area Under Curve; Blood Glucose; Child; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Peptides; Postprandial Period; Single-Blind Method; Venoms | 2009 |
Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.
Topics: Adult; Amyloid; Area Under Curve; C-Peptide; Demography; Diabetes Mellitus, Type 1; Exenatide; Female; Glucagon; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Middle Aged; Peptides; Primary Graft Dysfunction; Prospective Studies; Transplantation, Homologous; Venoms | 2009 |
Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.
Topics: Adult; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood Glucose; C-Peptide; Down-Regulation; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Intestinal Mucosa; Intestines; Kinetics; Liver; Male; Models, Biological; Ontario; Peptides; Postprandial Period; Receptors, Glucagon; Reference Values; Triglycerides; Venoms | 2012 |
Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
Topics: Animals; Blood Glucose; Cattle; Cattle Diseases; Dose-Response Relationship, Drug; Exenatide; Glucagon; Glucagon-Like Peptide 1; Hypoglycemia; Insulin; Male; Oxyntomodulin; Peptides; Radioimmunoassay; Venoms | 2013 |
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Metformin; Middle Aged; Peptides; Postprandial Period; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Diabetes Mellitus, Type 1; Exenatide; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Venoms; Young Adult | 2014 |
Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Topics: Adult; Blood Glucose; C-Peptide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Exenatide; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Venoms; Young Adult | 2014 |
Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Topics: Adolescent; Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 1; Exenatide; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Islet Amyloid Polypeptide; Male; Pancreas, Artificial; Peptides; Venoms; Young Adult | 2014 |
Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
Topics: Adipose Tissue; Adult; Blood Glucose; Exenatide; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lipolysis; Liver; Male; Middle Aged; Obesity, Morbid; Peptides; Postprandial Period; Venoms | 2017 |
The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Glucagon; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Male; Middle Aged; Peptides; Prognosis; Venoms; Young Adult | 2018 |
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
Topics: Adult; Blood Glucose; Catecholamines; Cross-Over Studies; Exenatide; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Heart Rate; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Incretins; Male; Middle Aged; Parasympathetic Nervous System; Postoperative Period; Sympathetic Nervous System | 2019 |
Topics: Adipose Tissue, White; Adult; Aged; Air Pollutants; Animals; Anti-Inflammatory Agents; Arginine; bcl-2-Associated X Protein; Biofuels; Biological Products; Blood Glucose; Breast Neoplasms; Caspases; CD36 Antigens; Cell Communication; Cell Proliferation; Cell Survival; Cooking; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diphtheria Toxin; Double-Blind Method; Exenatide; Extracellular Polymeric Substance Matrix; Feasibility Studies; Female; Filgrastim; Fruit; Galactose; Gene Deletion; Gene Knockdown Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glycated Hemoglobin; Hematopoietic Stem Cell Mobilization; Household Articles; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Lung; Lymphoma; Male; Metals, Heavy; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Nanoparticles; Neoplasms; Obesity; Obstetrics; Odds Ratio; Oxygen; Peripheral Blood Stem Cell Transplantation; Photochemotherapy; Plant Extracts; Polyethylene Glycols; Polyglutamic Acid; Porosity; Postprandial Period; Prospective Studies; Quality of Life; Receptors, Glucagon; Receptors, LDL; Receptors, Somatostatin; Registries; Rhodophyta; Rhodotorula; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction; Somatostatin; Stilbenes; Terminalia; Treatment Outcome; United States; Venoms | 2021 |
129 other study(ies) available for glucagon and exenatide
| Article | Year |
|---|---|
Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.
Topics: Amino Acid Sequence; Animals; Cyclic AMP; Exenatide; Glucagon; Glucagon-Like Peptide 1; Guinea Pigs; Lizards; Male; Molecular Sequence Data; Pancreas; Peptide Fragments; Peptides; Protein Precursors; Receptors, Gastrointestinal Hormone; Venoms | 1992 |
Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig.
Topics: Amino Acid Sequence; Animals; Chromatography, High Pressure Liquid; Cyclic AMP; Exenatide; Gastric Mucosa; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Guinea Pigs; Iodine Radioisotopes; Male; Molecular Sequence Data; Pancreas; Peptides; Receptors, Gastrointestinal Hormone; Structure-Activity Relationship; Tyrosine; Venoms | 1994 |
Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Topics: Animals; Drug Interactions; Exenatide; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucose; Insulin; Male; Peptide Fragments; Peptides; Protein Precursors; Radioimmunoassay; Rats; Rats, Wistar; Receptors, Glucagon; Venoms | 1995 |
Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2.
Topics: Aminopyrine; Animals; Binding, Competitive; Cell Membrane; Cross-Linking Reagents; Cyclic AMP; Exenatide; Female; Gastric Acid; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Histamine; In Vitro Techniques; Lizards; Parietal Cells, Gastric; Peptide Fragments; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Venoms | 1994 |
Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide.
Topics: Animals; Exenatide; Gastric Juice; Gastrins; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; In Vitro Techniques; Male; Peptide Fragments; Peptides; Rats; Rats, Sprague-Dawley; Somatostatin; Venoms | 1994 |
Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
Topics: Animals; CHO Cells; Cricetinae; Evaluation Studies as Topic; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Lizards; Neurotransmitter Agents; Oxyntomodulin; Peptide Fragments; Peptides; Rats; Receptors, Cell Surface; Receptors, Glucagon; Venoms | 1994 |
Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.
Topics: Aminopyrine; Animals; Blotting, Northern; Cell Separation; Cross-Linking Reagents; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Kinetics; Parietal Cells, Gastric; Peptide Fragments; Peptides; Radioligand Assay; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Glucagon; RNA, Messenger; Venoms | 1994 |
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Topics: Animals; Binding, Competitive; Cell Line; Cell Membrane; Cyclic AMP; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Insulin; Insulin Secretion; Insulinoma; Kinetics; Lizards; Lung; Pancreatic Neoplasms; Peptide Fragments; Peptides; Rats; Receptors, Cell Surface; Receptors, Glucagon; Tumor Cells, Cultured; Venoms | 1993 |
Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites.
Topics: Animals; Autoradiography; Binding Sites; Brain; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Kinetics; Male; Peptide Fragments; Peptides; Radioligand Assay; Rats; Rats, Wistar; Venoms | 1995 |
Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary.
Topics: Animals; Autoradiography; Binding Sites; Binding, Competitive; Exenatide; Glucagon; Glucagon-Like Peptide 1; Iodine Radioisotopes; Lizards; Male; Peptide Fragments; Peptides; Pituitary Gland, Posterior; Protein Precursors; Rats; Rats, Wistar; Vasoactive Intestinal Peptide; Venoms | 1995 |
The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cell Line; Chlorocebus aethiops; Cyclic AMP; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Peptide Fragments; Peptides; Protein Precursors; Rats; Receptors, Glucagon; Recombinant Fusion Proteins; Venoms | 1996 |
Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
Topics: Animals; Blood Pressure; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Heart Rate; Male; Peptide Fragments; Peptides; Rats; Rats, Sprague-Dawley; Venoms | 1996 |
Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.
Topics: Amino Acid Sequence; Animals; Base Sequence; DNA, Complementary; Exenatide; Gene Expression Regulation; Glucagon; Lizards; Molecular Sequence Data; Peptides; Proglucagon; Protein Precursors; RNA, Messenger; Salivary Glands; Sequence Homology, Amino Acid; Venoms | 1997 |
Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
Topics: Animals; Cyclic AMP; Energy Metabolism; Enzyme Activation; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glycogen; Glycogen Synthase; Insulin; Liver; Muscle, Skeletal; Peptide Fragments; Peptides; Phosphorylase a; Rats; Rats, Wistar; Venoms | 1997 |
High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Topics: Amino Acid Sequence; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cyclic AMP; Exenatide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Molecular Sequence Data; Peptide Fragments; Peptides; Rats; Receptors, Glucagon; Recombinant Fusion Proteins; Sequence Deletion; Structure-Activity Relationship; Transfection; Venoms | 1997 |
Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Exenatide; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Lipolysis; Mice; Peptide Fragments; Peptides; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Venoms | 1997 |
Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea.
Topics: Animals; Exenatide; Glucagon; Glucagon-Like Peptide 1; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Male; Mucus; Neuropeptides; Peptide Fragments; Peptide PHI; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Protease Inhibitors; Protein Precursors; Rats; Rats, Sprague-Dawley; Thiorphan; Trachea; Vasoactive Intestinal Peptide; Venoms | 1998 |
Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.
Topics: Animals; Calcium; Cyclic AMP; Cytoplasm; Dose-Response Relationship, Drug; Exenatide; Food Deprivation; Glucagon; Glucagon-Like Peptide 1; Gonadotropin-Releasing Hormone; Hypothalamus; Luteinizing Hormone; Male; Mice; Mice, Transgenic; Neurons; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Wistar; Receptors, Cell Surface; Time Factors; Tumor Cells, Cultured; Venoms | 1998 |
Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homolog
Topics: Amino Acid Sequence; Animals; Base Sequence; Chickens; Cloning, Molecular; DNA Primers; DNA, Complementary; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Intercellular Signaling Peptides and Proteins; Lizards; Mammals; Molecular Sequence Data; Neuropeptides; Peptide Fragments; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Polymerase Chain Reaction; Protein Precursors; Rats; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Trout; Vasoactive Intestinal Peptide; Venoms | 1998 |
Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones.
Topics: Amino Acid Sequence; Animals; Black Widow Spider; Calcium Signaling; Cells, Cultured; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Molecular Mimicry; Molecular Sequence Data; Neurotoxins; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Sequence Homology, Amino Acid; Spider Venoms; Venoms | 1998 |
Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Topics: Animals; Blood Glucose; Body Weight; Carrier Proteins; Crosses, Genetic; Cyclic AMP; Diabetes Mellitus, Type 2; Drug Administration Schedule; Energy Intake; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Insulin; Islets of Langerhans; Lizards; Mice; Mice, Inbred C57BL; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Leptin; Venoms | 1999 |
Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Topics: Animals; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Kinetics; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Zucker; Sequence Homology; Venoms | 1999 |
Functional studies of a glucagon receptor isolated from frog Rana tigrina rugulosa: implications on the molecular evolution of glucagon receptors in vertebrates.
Topics: Amino Acid Sequence; Animals; Binding, Competitive; CHO Cells; COS Cells; Cricetinae; Cyclic AMP; Evolution, Molecular; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Neuropeptides; Peptide Fragments; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors; Ranidae; Receptors, Glucagon; Recombinant Proteins; Secretin; Sequence Homology, Amino Acid; Species Specificity; Vasoactive Intestinal Peptide; Venoms; Vertebrates; Zebrafish | 1999 |
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Islets of Langerhans; Male; Pancreatectomy; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Venoms | 1999 |
Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.
Topics: Adenylyl Cyclases; Amylases; Animals; Cell Cycle; Cell Differentiation; Cholecystokinin; Dexamethasone; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Insulin; Kinetics; Pancreatic Neoplasms; Peptide Fragments; Peptides; Protein Precursors; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Venoms | 1999 |
The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.
Topics: Animals; Electrophysiology; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Injections, Intravenous; Liver; Male; Neurons, Afferent; Pancreas; Peptide Fragments; Peptides; Portal Vein; Rats; Rats, Wistar; Receptors, Glucagon; Vagus Nerve; Venoms | 2000 |
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
Topics: Amines; Animals; Appetite; Body Weight; Brain; Diabetes Mellitus; Drinking; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; In Situ Hybridization; Injections, Intraventricular; Injections, Subcutaneous; Male; Obesity; Peptide Fragments; Peptides; Rats; Rats, Wistar; Rats, Zucker; Receptors, Glucagon; RNA, Messenger; Venoms | 2000 |
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Topics: Adult; Animals; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Insulin; Insulinoma; Male; Monocytes; Pancreatic Neoplasms; Peptide Fragments; Peptides; Proinsulin; Protein Precursors; Rats; Receptors, Glucagon; Tumor Cells, Cultured; Venoms | 2000 |
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
Topics: Animals; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Homeodomain Proteins; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Peptide Fragments; Peptides; Promoter Regions, Genetic; Protein Precursors; Trans-Activators; Venoms | 2000 |
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Topics: Animals; Blood Glucose; Culture Techniques; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Venoms | 2001 |
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Animals; Area Under Curve; Blood Glucose; Depression, Chemical; Energy Intake; Energy Metabolism; Exenatide; Fasting; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Hormones; Humans; Infusions, Intravenous; Insulin; Lizards; Male; Nausea; Peptide Fragments; Peptides; Postprandial Period; Protein Precursors; Satiety Response; Venoms | 2001 |
Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Topics: Animals; Animals, Newborn; Apoptosis; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Immunohistochemistry; Insulin; Islets of Langerhans; Organ Size; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Wistar; Venoms | 2001 |
A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats.
Topics: Animals; Appetite Regulation; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Energy Intake; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Injections, Intraperitoneal; Male; Peptide Fragments; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Time Factors; Venoms | 2001 |
Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states.
Topics: Amino Acid Sequence; Binding Sites; Circular Dichroism; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glycine; Humans; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Mutation; Peptide Fragments; Peptides; Phosphatidylcholines; Protein Precursors; Protein Structure, Secondary; Sequence Homology, Amino Acid; Stereoisomerism; Trifluoroethanol; Tryptophan; Venoms | 2001 |
Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1.
Topics: Amino Acid Sequence; Circular Dichroism; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Protein Structure, Secondary; Sequence Homology, Amino Acid; Venoms | 2002 |
Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
Topics: Animals; Autocrine Communication; Cell Line; Diabetes Mellitus; Enzyme Inhibitors; Exenatide; Gene Expression Regulation; Genetic Engineering; Glucagon; Glucagon-Like Peptide 1; Indoles; Insulin; Insulinoma; Islets of Langerhans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Promoter Regions, Genetic; Protein Kinase C; Protein Precursors; Rats; Receptors, Peptide; Recombinant Proteins; Research Design; Second Messenger Systems; Tumor Cells, Cultured; Venoms | 2002 |
Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.
Topics: Animals; Down-Regulation; Exenatide; Glucagon; Glucagon-Like Peptide 1; Hypothalamus; Injections, Intraventricular; Male; Neurons; Neurotransmitter Agents; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Serotonin; Venoms | 2002 |
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Topics: Amino Acid Sequence; Animals; Antimetabolites; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Differentiation; Cyclic AMP; DNA Replication; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Immunohistochemistry; L-Lactate Dehydrogenase; Molecular Sequence Data; Nerve Growth Factor; Neurodegenerative Diseases; PC12 Cells; Peptide Fragments; Peptides; Protein Precursors; Rats; Receptors, Glucagon; Stimulation, Chemical; Tetrazolium Salts; Thiazoles; Venoms | 2002 |
Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.
Topics: Animals; Drug Interactions; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin Resistance; Muscle, Skeletal; Peptide Fragments; Peptides; Phosphatidylinositol 3-Kinases; Protein Precursors; Rats; Tumor Cells, Cultured; Venoms | 2002 |
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Topics: Age Factors; Animals; Animals, Newborn; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Disease Models, Animal; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Secretion; Islets of Langerhans; Longitudinal Studies; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Mutant Strains; Rats, Wistar; Venoms | 2002 |
Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.
Topics: Animals; Chromatography, High Pressure Liquid; Exenatide; Glucagon; Glucagon-Like Peptide 1; Kidney Cortex; Kinetics; Microvilli; Peptide Fragments; Peptides; Protein Precursors; Rats; Swine; Venoms | 2002 |
Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
Topics: Analysis of Variance; Cells, Cultured; Culture Techniques; Dose-Response Relationship, Drug; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glycogen Phosphorylase; Glycogen Synthase; Humans; Isoenzymes; Muscle, Skeletal; Myocardium; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Second Messenger Systems; Venoms | 2002 |
Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors.
Topics: Cell Differentiation; Cell Line; Cyclic AMP; DNA-Binding Proteins; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hepatocyte Nuclear Factor 3-beta; Homeodomain Proteins; Humans; Insulin; Islets of Langerhans; Mitogen-Activated Protein Kinases; Nuclear Proteins; Pancreatic Ducts; Peptide Fragments; Peptides; Promoter Regions, Genetic; Protein Precursors; Receptors, Glucagon; Trans-Activators; Transcription Factors; Transfection; Venoms | 2002 |
Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.
Topics: Animals; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Peptides; Proglucagon; Protein Precursors; Radioimmunoassay; Rats; Rats, Wistar; Thyrotropin; Time Factors; Venoms | 2002 |
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
Topics: Animals; Basal Ganglia; Cell Death; Cell Survival; Cells, Cultured; Choline O-Acetyltransferase; Cyclic AMP; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Exenatide; Glial Fibrillary Acidic Protein; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glutamic Acid; Hippocampus; Ibotenic Acid; Immunohistochemistry; Nerve Degeneration; Neurons; Parasympathetic Nervous System; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Glucagon; Venoms | 2002 |
Cellular specificity of proexendin-4 processing in mammalian cells in vitro and in vivo.
Topics: Adrenocorticotropic Hormone; Animals; Antibody Specificity; Cell Line; Chromatography, High Pressure Liquid; Cricetinae; Exenatide; Female; Fibroblasts; Glucagon; Glucagon-Like Peptide 1; Immunohistochemistry; Islets of Langerhans; Kidney; Male; Mice; Mice, Transgenic; Organ Specificity; Peptide Fragments; Peptides; Pituitary Gland; Protein Precursors; Radioimmunoassay; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Venoms | 2002 |
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
Topics: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Eating; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Islets of Langerhans; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2002 |
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Topics: Animals; Apoptosis; Blood Glucose; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 1; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2002 |
Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Topics: Adult; Animals; Biotransformation; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl Peptidase 4; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Human Growth Hormone; Humans; Hydrocortisone; Infusions, Intravenous; Insulin; Kinetics; Lizards; Peptide Fragments; Peptides; Reference Values; Venoms | 2002 |
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Topics: Animals; Apoptosis; beta Catenin; Blood Glucose; Cell Line; Cell Survival; Colforsin; Cricetinae; Cycloheximide; Cytokines; Cytoskeletal Proteins; Diabetes Mellitus, Experimental; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; In Situ Nick-End Labeling; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptide Fragments; Peptides; Protein Precursors; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptors, Glucagon; Signal Transduction; Streptozocin; Trans-Activators; Venoms | 2003 |
The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
Topics: Amino Acid Sequence; Binding, Competitive; Cell Line; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Models, Molecular; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Recombinant Proteins; Venoms | 2003 |
Pharmacologic treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Monosaccharide Transport Proteins; Obesity; Peptide Fragments; Peptide Hormones; Peptides; Peroxisome Proliferators; Protein Precursors; Receptors, Cell Surface; Thiazoles; Venoms | 2003 |
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.
Topics: Animals; Area Postrema; Autonomic Pathways; Catecholamines; Cell Line; Central Nervous System; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Immunohistochemistry; In Situ Hybridization; Male; Neurons; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; RNA, Messenger; Solitary Nucleus; Transcriptional Activation; Tyrosine 3-Monooxygenase; Venoms | 2003 |
Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Secretion; Islets of Langerhans; Leptin; Liver Glycogen; Peptide Fragments; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Venoms | 2003 |
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Death; Down-Regulation; Exenatide; Fetus; Glucagon; Glucagon-Like Peptide 1; Hippocampus; Iron; Male; Mice; Mice, Inbred Strains; Neurons; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Venoms | 2003 |
Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas.
Topics: Animals; Exenatide; Glucagon; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Venoms | 2003 |
A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Topics: Amino Acid Sequence; Cell Line; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Kinetics; Ligands; Models, Biological; Molecular Sequence Data; Peptide Fragments; Peptides; Plasmids; Protein Binding; Protein Precursors; Receptors, Glucagon; Sequence Homology, Amino Acid; Transfection; Venoms | 2003 |
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
Topics: Androstadienes; Animals; Blotting, Western; Catalysis; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Electrophysiology; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Kinetics; Male; Mice; Peptide Fragments; Peptides; Phosphatidylinositol 3-Kinases; Phosphorylation; Potassium; Precipitin Tests; Protein Precursors; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Time Factors; Transcriptional Activation; Tyrphostins; Up-Regulation; Venoms; Wortmannin | 2003 |
The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Topics: Amino Acid Sequence; Animals; Binding Sites; Cell Line; Cell Membrane; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Inhibitory Concentration 50; Ligands; Models, Biological; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Rats; Receptors, Glucagon; Venoms | 2004 |
Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
Topics: Amino Acid Sequence; Animals; Cell Line; Cyclic AMP; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Inhibitory Concentration 50; Ligands; Methionine; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Rats; Receptors, Glucagon; Sequence Alignment; Sequence Deletion; Tyrosine; Venoms | 2004 |
A gut response. The next generation of type 2 drugs.
Topics: Diabetes Mellitus, Type 2; Exenatide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Peptide Fragments; Peptide Hormones; Peptide YY; Peptides; Protein Precursors; United States; Venoms | 2004 |
GLP-1: target for a new class of antidiabetic agents?
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Topics: Amino Acid Sequence; Animals; Binding, Competitive; Brain; Cells, Cultured; Cricetinae; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Injections, Intraperitoneal; Injections, Intraventricular; Iodine Radioisotopes; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Sequence Data; Oxyntomodulin; Peptide Fragments; Peptides; Proglucagon; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Receptors, G-Protein-Coupled; Receptors, Glucagon; Venoms | 2004 |
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms | 2004 |
A gut feeling.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Redox-mediated enrichment of self-renewing adult human pancreatic cells that possess endocrine differentiation potential.
Topics: Acetylcysteine; Adenoviridae; Adult; Albumins; alpha-Amylases; C-Peptide; Cell Aggregation; Cell Differentiation; Cell Separation; Cells, Cultured; Chromones; Culture Media; Culture Media, Serum-Free; Exenatide; Gene Expression Regulation; Genetic Vectors; Glucagon; Homeodomain Proteins; Humans; Insulin; Intermediate Filament Proteins; Intracellular Fluid; Islets of Langerhans; Morpholines; Nerve Tissue Proteins; Nestin; Niacinamide; Oxidation-Reduction; Peptides; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Stem Cells; Trans-Activators; Transcription Factors; Venoms; Vimentin | 2004 |
Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal.
Topics: Action Potentials; Afferent Pathways; Animals; Arousal; Choline; Digestive System; Eating; Exenatide; Genes, Reporter; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glutamic Acid; Hypothalamic Hormones; Hypothalamus; Intracellular Signaling Peptides and Proteins; Melanins; Mice; Mice, Transgenic; Neurons; Neuropeptides; Orexin Receptors; Orexins; Paraventricular Hypothalamic Nucleus; Patch-Clamp Techniques; Peptide Fragments; Peptides; Pituitary Hormones; Protein Precursors; Receptors, G-Protein-Coupled; Receptors, Glucagon; Receptors, Neuropeptide; Sodium Channel Blockers; Solitary Nucleus; Synaptic Transmission; Tetrodotoxin; Venoms; Viscera | 2004 |
Interplay of glucagon-like peptide-1 and transforming growth factor-beta signaling in insulin-positive differentiation of AR42J cells.
Topics: Animals; Cell Differentiation; Cell Line; DNA Primers; Equidae; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin; Oligonucleotides, Antisense; Peptide Fragments; Peptides; Polymerase Chain Reaction; Protein Precursors; Signal Transduction; Transforming Growth Factor beta; Venoms | 2004 |
Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.
Topics: Animals; Blood Glucose; Body Weight; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Insulin; Islets of Langerhans; Male; Obesity; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Zucker; Venoms | 2005 |
Effect of GLP-1 on glucose transport and its cell signalling in human myocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Aged, 80 and over; Androstadienes; Biological Transport; Cells, Cultured; Enzyme Activation; Exenatide; Female; Flavonoids; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Indoles; Insulin; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Cells; Peptide Fragments; Peptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Venoms; Wortmannin | 2005 |
beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
Topics: Animals; Blood Glucose; Cell Division; Cell Survival; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Homeodomain Proteins; Homeostasis; Islets of Langerhans; Mice; Mice, Knockout; Mice, Mutant Strains; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Trans-Activators; Venoms | 2005 |
Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Oxidative Stress; Peptide Fragments; Peptides; Rats; Rats, Wistar; Streptozocin; Vasodilator Agents; Venoms | 2005 |
[The role of incretins. Type 2 diabetes with new beginnings].
Topics: Diabetes Mellitus, Type 2; Disease Progression; Exenatide; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2005 |
Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells.
Topics: Animals; Benzothiazoles; Blotting, Western; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Diamines; DNA Primers; DNA-Binding Proteins; Dose-Response Relationship, Drug; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin; Islets of Langerhans; Ligands; Organic Chemicals; Peptide Fragments; Peptides; Phosphoproteins; Polymerase Chain Reaction; Protein Binding; Protein Isoforms; Protein Precursors; Quinolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Smad Proteins; Smad1 Protein; Smad5 Protein; Smad8 Protein; Trans-Activators; Transforming Growth Factor beta; Venoms | 2005 |
Exenatide.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Molecular Sequence Data; Peptides; Sulfonylurea Compounds; Venoms | 2005 |
Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells.
Topics: Animals; C-Peptide; Cell Differentiation; Cell Line; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Immunohistochemistry; Insulin; Insulin Secretion; Mice; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Venoms | 2005 |
Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.
Topics: Adipocytes; Animals; Biological Transport, Active; Deoxyglucose; Diabetes Mellitus, Experimental; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; In Vitro Techniques; Lipid Metabolism; Lipids; Lipolysis; Male; Peptide Fragments; Peptides; Protein Kinases; Protein Precursors; Rats; Rats, Wistar; Venoms | 2005 |
[Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin Resistance; Lizards; Peptide Fragments; Peptides; Protein Precursors; Time Factors; Venoms | 2005 |
Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Body Temperature; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Eating; Electrocardiography; Epinephrine; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Heart; Heart Rate; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Norepinephrine; Oxyntomodulin; Peptides; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Telemetry; Venoms | 2007 |
Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets.
Topics: Arginine; Exenatide; Female; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Membrane Proteins; Middle Aged; Organ Culture Techniques; Peptides; Receptors, Somatostatin; Venoms | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Kisspeptin-13 inhibits insulin secretion without affecting glucagon or somatostatin release: study in the perfused rat pancreas.
Topics: Animals; Arginine; Carbachol; Dose-Response Relationship, Drug; Exenatide; Glucagon; In Vitro Techniques; Insulin; Insulin Antagonists; Insulin Secretion; Kisspeptins; Male; Pancreas; Peptides; Pertussis Toxin; Proteins; Rats; Rats, Wistar; Somatostatin; Venoms | 2008 |
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Gastric Emptying; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Triglycerides; Venoms | 2008 |
Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Topics: Animals; Blood Glucose; Dogs; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islets of Langerhans; Peptide Fragments; Peptides; Postprandial Period; Venoms | 2008 |
The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
Topics: Adult; Amyloid; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Exenatide; Feasibility Studies; Glucagon; Graft Rejection; Graft Survival; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Islet Amyloid Polypeptide; Islets of Langerhans Transplantation; Middle Aged; Peptides; Prospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome; Venoms | 2008 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.
Topics: Adult; Bicycling; Blood Glucose; Catecholamines; Diabetes Mellitus, Type 2; Exenatide; Exercise; Glucagon; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Lactates; Male; Oxygen Consumption; Peptides; Reference Values; Venoms | 2010 |
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Peptides; Phenotype; Receptors, Glucagon; Venoms | 2009 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Venoms | 2011 |
Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Topics: Animals; Blotting, Western; Calcineurin; Calcium; Cell Differentiation; Cell Line; Cytosol; Exenatide; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Muscle Fibers, Skeletal; Myoblasts; Myosin Heavy Chains; Peptide Fragments; Peptides; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Protein Isoforms; Receptors, Glucagon; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trans-Activators; Transcription Factors; Venoms | 2011 |
GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disulfides; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Half-Life; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Molecular Sequence Data; Peptides; Protein Binding; Protein Stability; Rats; Venoms | 2011 |
Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Topics: Adipose Tissue; Animals; Biological Transport; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Transporter Type 2; Glucose Transporter Type 4; Glycogen Synthase; Insulin Resistance; Liver; Male; Mitogen-Activated Protein Kinases; Muscle, Skeletal; Peptides; Phosphatidylinositol 3-Kinases; Rats; Rats, Wistar; Venoms | 2012 |
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Blood Glucose; Cross Reactions; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Time Factors; Treatment Outcome; Venoms | 2012 |
Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Enzyme Activation; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Peptides; Venoms | 2012 |
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Topics: Adamantane; Animals; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Insulin-Secreting Cells; Leupeptins; Mice; Mice, Transgenic; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2012 |
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastrins; Glucagon; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred Strains; Mice, Obese; Obesity; Omeprazole; Peptides; Venoms | 2013 |
Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
Topics: Animals; Artificial Intelligence; Diabetes Mellitus, Type 2; Exenatide; Expert Systems; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; High-Throughput Screening Assays; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Obesity; Pattern Recognition, Automated; Peptides; Rats; Rats, Zucker; Somatostatin; Somatostatin-Secreting Cells; Venoms | 2013 |
The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Topics: Animals; Animals, Newborn; Biomarkers; Blood Glucose; Body Weight; Cell Proliferation; Clusterin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gene Expression; Glucagon; Homeodomain Proteins; Hypoglycemic Agents; In Situ Hybridization; Insulin-Secreting Cells; Peptides; Rats; Rats, Wistar; Regeneration; RNA, Messenger; Trans-Activators; Venoms | 2013 |
Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF.
Topics: Calcitonin; Chromatography, High Pressure Liquid; Deamino Arginine Vasopressin; Enfuvirtide; Exenatide; Glucagon; HIV Envelope Protein gp41; Humans; Mass Spectrometry; Peptide Fragments; Peptides; Sensitivity and Specificity; Somatostatin; Venoms | 2013 |
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; Blood Pressure; Body Weight; Cell Line; Cricetinae; Duodenum; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Haplorhini; Heart Rate; Humans; Insulin; Insulin Secretion; Ligands; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Protein Binding; Receptors, Glucagon; Tissue Distribution; Transfection; Venoms | 2014 |
Generation of high-yield insulin producing cells from human bone marrow mesenchymal stem cells.
Topics: Activins; Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Culture Media; Exenatide; Gene Expression; Glucagon; Hepatocyte Growth Factor; Hepatocyte Nuclear Factor 3-beta; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Incretins; Insulin; Insulin-Secreting Cells; Mesenchymal Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Peptides; Somatostatin; SOXF Transcription Factors; Taurine; Trans-Activators; Transcription Factors; Venoms; Zebrafish Proteins | 2014 |
Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity.
Topics: Animals; beta-Endorphin; Cells, Cultured; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Hyperalgesia; Microglia; Neuralgia; Nociception; Peptide Fragments; Peptides; Posterior Horn Cells; Rats; Rats, Wistar; Receptors, Glucagon; Venoms | 2014 |
The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
Topics: Animals; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Exenatide; Fluorescent Antibody Technique; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glutathione Reductase; Insulin; Insulin Secretion; Islets of Langerhans; Kidney; Lipids; Liver; Male; Peptides; Rats, Wistar; Time Factors; Venoms | 2014 |
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms | 2014 |
Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Diabetes Mellitus; Drug Synergism; Exenatide; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Clamp Technique; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Microspheres; Peptides; Venoms | 2015 |
The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Topics: Animals; Apoptosis; Blood Glucose; C-Peptide; Cell Count; Diabetes Mellitus, Experimental; Exenatide; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Graft Survival; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice, Inbred BALB C; Models, Animal; Peptides; Venoms | 2015 |
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Exenatide; Glucagon; Insulin; Mice; Obesity; Peptides; Satiation; Sincalide; Venoms | 2015 |
Rapid, high efficiency isolation of pancreatic ß-cells.
Topics: Animals; Boron Compounds; Cell Separation; Diabetes Mellitus, Experimental; Exenatide; Female; Gene Expression Profiling; Glucagon; Insulin; Insulin-Secreting Cells; Mice, Inbred C57BL; Mice, Inbred NOD; Peptides; Somatostatin; Venoms | 2015 |
Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
Topics: Actins; Amylases; Animals; Cell Line, Tumor; Cells, Cultured; Exenatide; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Injections, Intravenous; Ki-67 Antigen; Male; Oxyntomodulin; Pancreas, Exocrine; Peptides; Proglucagon; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Venoms | 2016 |
A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.
Topics: Absorptiometry, Photon; Adipokines; Adiponectin; Animals; Body Composition; Cats; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Insulin Secretion; Leptin; Male; Obesity; Peptides; Venoms | 2016 |
Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
Topics: Animals; Blood Glucose; Body Composition; Disease Models, Animal; Dogs; Eating; Energy Metabolism; Exenatide; Fasting; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liver; Male; Peptides; Prediabetic State; Venoms | 2016 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Body Weight; Drug Design; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Mice, Inbred C57BL; Mice, Obese; Molecular Docking Simulation; Obesity; Peptides; Structure-Activity Relationship; Swine; Venoms | 2017 |
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Topics: Animals; Exenatide; Glucagon; Glucagon-Like Peptide 1; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Peptides; Receptors, Glucagon; Venoms | 2018 |
Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats.
Topics: Animals; Blood Glucose; Burns; Disease Models, Animal; Exenatide; Glucagon; Insulin; Islets of Langerhans; Male; Rats; Rats, Wistar; RNA, Messenger | 2018 |
Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Cell Line; Cyclic AMP; Diabetes Mellitus; Dideoxyadenosine; Diet, High-Fat; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Mice; Mice, Obese; Peptides; Venoms | 2018 |
Effects of Exendin-4 on pancreatic islets function in treating hyperglycemia post severe scald injury in rats.
Topics: Animals; Burns; Exenatide; Glucagon; Glucose Tolerance Test; Hyperglycemia; Insulin; Islets of Langerhans; Rats; Rats, Wistar | 2018 |
Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Topics: Animals; Chlorocebus aethiops; COS Cells; Cyclic AMP; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin Secretion; Islets of Langerhans; Mice, Inbred C57BL; Perfusion; Signal Transduction | 2018 |
Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
Topics: Animals; Body Weight; Diet, High-Fat; Drug Interactions; Energy Metabolism; Exenatide; Gastrins; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolism; Mice; Pancreas; Peptide Fragments; Time Factors | 2019 |
GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.
Topics: Animals; Diet, High-Fat; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice, Inbred C57BL; Signal Transduction | 2021 |
Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
Topics: Animals; Appetite; Appetite Depressants; Blood Glucose; Cholecystokinin; Exenatide; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Neurons; Receptors, Gastrointestinal Hormone | 2022 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diet, High-Fat; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Insulin; Mice; Receptors, Glucagon | 2022 |
Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.
Topics: Animals; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Heart; Ischemia; Myocardial Contraction; Rats; Reperfusion | 2023 |
Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
Topics: Adolescent; Child; Exenatide; Glicentin; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycemic Control; Humans; Insulin; Pediatric Obesity; Proinsulin | 2023 |